{"nctId":"NCT04915729","briefTitle":"A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity","startDateStruct":{"date":"2021-06-22","type":"ACTUAL"},"conditions":["Stroke"],"count":1489,"armGroups":[{"label":"Tenecteplase treatment group","type":"EXPERIMENTAL","interventionNames":["Drug: tenecteplase"]},{"label":"Alteplase active control group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: alteplase"]}],"interventions":[{"name":"tenecteplase","otherNames":[]},{"name":"alteplase","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years old\n* Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (0\\< NIHSS ≤25); if NIHSS \\<4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1)\n* Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation\n* Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset\n* Patients with premorbid modified Rankin Scale (mRS) 0 or 1\n* Signed and dated written informed consent in accordance with good clinical practice (GCP) and local legislation prior to trial admission\n\nExclusion Criteria:\n\n* Evidence of intracranial haemorrhage on the Computed tomography (CT) scan or symptoms suggestive of subarachnoid haemorrhage, even if the CT scan is normal\n* Patients who must or are expected to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial\n* Acute bleeding diathesis, including but not limited to\n\n  * Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)\n  * Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement\n  * Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) \\> 1.7 or Prothrombin time (PT)\\>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range\n  * Platelet count of below 100,000/mm3 at screening\n  * Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)\n  * Recent traumatic external heart massage, obstetrical delivery, or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days\n  * Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm\n  * Neoplasm with increased haemorrhagic risk\n  * Documented ulcerative gastrointestinal disease during the last 3 m, oesophageal varices, arterial aneurysm, or arterial/venous malformations\n  * Any known disorder associated with a significant increased risk of bleeding\n* Bacterial endocarditis or pericarditis at screening\n* Acute pancreatitis at screening\n* Significant trauma or major surgery (according to the investigator's assessment) in the past 3 m\n* Imaging demonstrates multi-lobar infarction (hypodensity \\>1/3 cerebral hemisphere)\n* Severe uncontrolled arterial hypertension, e.g. systolic blood pressure (BP) \\>185 mmHg or diastolic BP \\>110 mmHg Further exclusion criteria apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1","description":"Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90.\n\nPercentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Major Neurological Improvement (National Institutes of Health Stroke Scale (NIHSS) Score of 0 or Improvement of at Least 4 Points Compared With Baseline","description":"Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.\n\nindivudal domains: level of consciousness (LOC), best gaze, visual fields, facial paresis, motor function arms, motor function legs, limb ataxia, sensory, language, dysarthria, extinction and inattention.\n\nMild strokes (NIHSS \\< 6): High likelihood of good recovery and independence, Moderate strokes (NIHSS 6-15): Variable outcomes depending on timely intervention, Severe strokes (NIHSS \\> 15): Lower likelihood of recovery without significant disability and higher risk of mortality.\n\nPercentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"45.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2","description":"Percentage of participants with Modified Rankin Scale (mRS) score of 0-2 is presented.\n\nModified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90.\n\nPercentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9","spread":null},{"groupId":"OG001","value":"79.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline of National Institutes of Health Stroke Scale (NIHSS) Score","description":"Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.\n\nindivudal domains: level of consciousness (LOC), best gaze, visual fields, facial paresis, motor function arms, motor function legs, limb ataxia, sensory, language, dysarthria, extinction and inattention.\n\nRestricted maximum likelihood (REML) based MMRM approach used to compare change from baseline in NIHSS score at day 90. If patient misses visit, missing data will not be imputed. The mixed effect model will handle missing data based on a likelihood method under MAR assumption.\n\nChange in NIHSS score from baseline = overall mean + treatment + visit + baseline NIHSS + age + time to drug administration since onset of stroke symptoms + treatment by visit interaction + baseline NIHSS by visit interaction + random error.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.47","spread":"0.34"},{"groupId":"OG001","value":"-3.02","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Distribution of Modified Rankin Scale (mRS)","description":"Distribution of Modified Rankin Scale (mRS) is presented. Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":null},{"groupId":"OG001","value":"40.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"28.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"5.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Barthel Index Score ≥95","description":"The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.\n\nPercentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"73.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH) Per European Cooperative Acute Stroke Study (ECASS) Ⅲ Definition During On-treatment Period","description":"Percentage of participants with Symptomatic Intracerebral Haemorrhage (sICH) per European Cooperative Acute Stroke Study (ECASS) Ⅲ definition during on-treatment period is presented.\n\nPercentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died by Day 90","description":"Percentage of participants who died by day 90 is presented. Percentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6","description":"Percentage of participants with Modified Rankin Scale (mRS) score of 5 or 6 is presented.\n\nModified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death). It was measured at Day 90.\n\nPercentages are rounded to the nearest digits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"7.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":115,"n":736},"commonTop":["Constipation","Gingival bleeding","Hypokalaemia","Pneumonia","Urinary tract infection"]}}}